42,500 performance shares go to Benjamin Stone at First Tracks (TRAX), tied to share-price targets.

Share-price targets govern 42,500 performance shares granted to First Tracks (TRAX) medical chief.

First Tracks Biotherapeutics (NASDAQ:TRAX) Announces Earnings Results, Beats Estimates By $0.04 EPS

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics (TRAX) Stock Forecast & Analyst Ratings

First Tracks Biotherapeutics (Nasdaq:TRAX) - Stock Analysis

Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90

First Tracks Biotherapeutics Announces $200 Million Private Placement

First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors

Top biotechnology stock pick from Guggenheim

First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor

Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60

Evercore ISI Group Maintains Outperform on First Tracks, Raises Price Target to $70

7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data